Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
308 participants
INTERVENTIONAL
2013-04-30
2017-05-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This need for information varies over time. It is present before treatment begins, continues during treatment and persists after treatment. Given the specific features of radiotherapy, the manipulators are important interlocutors to participate in the accompanying caregiver time.
In conclusion, the quality of information delivered to the patient has been poorly evaluated, let alone with validated tools in this area.
The impact of information on the tolerance of the treatment also needs to be confirmed, knowing that an informed patient seems less anxious and better prepared for future treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validation of a Questionnaire in the French Language for the Patient Experience in Radiotherapy
NCT07133594
Interest of a Weekly Consultation by a Medical Electro Radiology Manipulator (MERM) in Addition to the Follow-up by the Radiotherapist to Improve the Collection of Radio-induced Toxicities in Patients Undergoing Proton Therapy
NCT05404308
Predictors of Normal Tissue Response From the Microenvironment in Radiotherapy for Prostate and Head-and-neck Cancer
NCT03294122
Contribution of the ENT (Ear, Nose, and Throat) Surgeon's Clinical Evaluation to the Contouring of Target Volumes and Organs Eligible for Radiotherapy in Head and Neck Cancers
NCT03265873
Geriatric-oncological Study on Quality of Life and Independence After Radiotherapy
NCT05187845
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A-Standard Care
standard care
Standard care
standard care
B-manipulator consultation radiotherapy added to standard care
manipulator consultation radiotherapy added to standard care
manipulator consultation radiotherapy added to standard care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard care
standard care
manipulator consultation radiotherapy added to standard care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient being treated by radiotherapy alone or combined with chemotherapy / immunotherapy, exclusive treatment or adjuvant
* Age over 18 years
Exclusion Criteria
* Patient with metastatic stage disease
* Patient targeted for hypofractionated radiotherapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Antoine Lacassagne
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Karen BENEZERY, md
Role: PRINCIPAL_INVESTIGATOR
Centre Antoine Lacassagne
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Antoine LACASSAGNE
Nice, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2012-A01601-42
Identifier Type: OTHER
Identifier Source: secondary_id
2012/63 INFORTH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.